Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias

Not Applicable

Terminated

• Conditions: Occipital Neuralgia
• Interventions: Other: Optimal Medical Management; Device: Occipital nerve stimulation

• Registration Number: NCT03475797
• Lead Sponsor: Nantes University Hospital

Brief Summary

Medically intractable pain caused by occipital neuralgia can be very difficult to control with traditional pain management. Peripheral nerve stimulation which is used in migraines and cluster headache can be an alternative for these patients with occipital neuralgias when medical treatment and traditional pain management have failed (drugs for neuropathic pain, infiltrations, psychobehavioral approaches and multidisciplinary approach in a pain center). Occipital nerve stimulation consists to put a lead subcutaneously in front of the occipital nerve and to connect the lead to a pulse generator. A retrospective study of 60 patients was conducted in Nantes University Hospital. The results were good with the Visual Analog Scale (VAS) decreased from 8.4 preoperatively to 2.85 postoperatively. The medical quantification scale (MQS) was reduced to about 50% (18 preoperatively versus 9.9 postoperatively). Stimulation was quiet stable over time with a mean follow-up of 24 months (range 6 to 72 months). The aim of StimO is to confirm this result through a national controlled randomized multicenter study where occipital nerve stimulation will be compared to the optimal medical management.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-03-16
• Study First Submitted QC: 2018-03-22
• Study First Posted: 2018-03-23
• Study Start: 2018-04-20
• Primary Completion: 2021-06-26
• Study Completion: 2021-09-03
• Status Verified: 2021-10
• Last Update Submitted: 2021-10-04
• Last Update Posted: 2021-10-11

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Patients between 18 and 85 years old
• Chronic occipital neuralgias as defined by International Headache Society (IHS) more than 6 months with permanent pain associated or not with paroxysm
• Secondary occipital neuralgias (post-traumatic, post-surgery, major arthrosis, compression or lesion of the occipital nerve ...)
• Chronic neuropathic pain according to the Neuropathic Pain Diagnostic Questionnaire (DN4 ≥ 4)
• Maximum pain on VAS ≥ 50/100
• Failure of medical treatment (association of neuropathic medication like antiepileptic and/or antidepressant and/or antalgic treatment like paracetamol, tramadol or morphine) and pain management in a pain Unit including multidisciplinary approach, physiotherapy, block test in C1-C2, radiofrequency rhizolysis, and/or corticosteroid infiltration of C2 according to the criteria defined by Health Authorities for spinal cord stimulation.
• Reduction of pain with Transcutaneous Electrical Nerve Stimulation (TENS) in occipital area
• Neurological examen has to be completed and must be normal except for the occipital neuralgia territory
• A negative pregnancy test for women with childbearing potential
• Women of childbearing potential must use appropriate method(s) of contraception during the clinical trial
• Patients must be capable of giving informed consent and must have signed informed consent
• Affiliation to an appropriate health insurance

Read More

Exclusion Criteria

• Contraindication to the experimental medical devices
• Titanium related allergies
• Patients with contraindications to general anesthesia
• Complete anaesthesia in the C2/Great occipital nerve territory
• Drug or alcohol addiction
• Psychiatric disorders (psychiatric evaluation)
• Any medical or psychological problems which may interfere with a smooth conduction of the study protocol (e.g. cancer with a limited life expectancy)
• Need for intensive nursing care
• Difficulty in follow-up
• Pregnant or lactating women
• Women not using contraception
• Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")
• Exclusion period for another study
• Simultaneous participation in another clinical trial except if that other trial does not affect the StimO study as approved and documented by the sponsor

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Optimal Medical Management (OMM)	Optimal Medical Management	Optimal Medical Management according to what is done in routine clinical practice
Occipital Nerve Stimulation (ONS)	Occipital nerve stimulation	Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management
Occipital Nerve Stimulation (ONS)	Optimal Medical Management	Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management

Primary Outcome Measures

Name	Time	Method
Efficacy of occipital nerve stimulation	6 months	Compare the decrease of pain (evaluated by visual analogic scale) after 6 months of treatment between the 2 groups (ONS / OMM)

Secondary Outcome Measures

Name	Time	Method
Relative decrease of pain (using Visual Analogic Scale) at 3 months	3 months	Comparison of the relative decrease of pain (using Visual Analogic Scale) at 3 months between the 2 groups (ONS/OMM)
Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months	3 months	Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months between the 2 groups (ONS/OMM)
Quality of life (using Hamilton Anxiety and Depression (HAD) scale)	Up to 6 months	Comparison of the quality of life (using Hamilton Anxiety and Depression (HAD) scale) between the 2 groups (ONS/OMM)
Maximum pain (using Visual Analogic Scale)	Up to 6 months	Comparison of maximum pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)
Relative decrease of pain (using Visual Analogic Scale) at 6 months	6 months	Comparison of the relative decrease of pain (using Visual Analogic Scale) at 6 months between the 2 groups (ONS/OMM)
Quality of life (using EQ-5D-5L questionnaire)	Up to 6 months	Comparison of the quality of life (using EQ-5D-5L questionnaire) between the 2 groups (ONS/OMM)
Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 6 months	6 months	Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 6 months of occipital nerve stimulation in the ONS group
Average pain (using Visual Analogic Scale)	Up to 6 months	Comparison of average pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)
Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 3 months	3 months	Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 3 months of occipital nerve stimulation in the ONS group
Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months	6 months	Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months between the 2 groups (ONS/OMM)

Trial Locations

Locations (10)

Hôpitaux Civils de Colmar; 🇫🇷 Colmar, France

Hôpital Pierre Wertheimer; 🇫🇷 Lyon, France

CHU de Caen; 🇫🇷 Caen, France

CHU de Clermont-Ferrand; 🇫🇷 Clermont-Ferrand, France

CHU Limoges; 🇫🇷 Limoges, France

CHU de Nice; 🇫🇷 Nice, France

Hôpital Lariboisière; 🇫🇷 Paris, France

CHU de Nantes; 🇫🇷 Nantes, France

Hôpital Foch; 🇫🇷 Paris, France

CHU de Poitiers; 🇫🇷 Poitiers, France